Skip to main content
OpenTrials
Completed

NCT Number: NCT03098628

Trial of Simplified Pneumococcal Vaccination in Vietnam II

This is a single-blind, open-label, randomised controlled trial with five groups. There are four different Pneumococcal Conjugate Vaccine (PCV) schedules to be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 week–10 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Pasteur Institute

Ho Chi Minh City, Vietnam

About this study

This is a single-blind, open-label, randomised controlled trial with five groups. There are four different PCV schedules to be evaluated: a 0+1 schedule of PCV10 at 12 months of age (Group V), a 0+1 schedule of PCV13 at 12 months of age (Group W), a 1+1 schedule of PCV10 at 2 and 12 months of age (Group X), and a 1+1 schedule of PCV13 at 2 and 12 months of age (Group Y); along with a control group that receives a dose of PCV10 at 24 months of age (Group Z). Additionally, all participants will receive four doses of Infanrix-hexa at 2, 3, 4 and 18 months of age.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 2 months and 2 months plus 2 weeks;
  • No significant maternal or perinatal history;
  • Born at or after 36 weeks gestation;
  • Written and signed informed consent from parent/legal guardian;
  • Lives within approximately 30 minutes of the commune health centre;
  • Family anticipates living in the study area for the next 22 months

Exclusion criteria

  • Known allergy to any component of the vaccine;
  • Allergic reaction or anaphylactic reaction to any previous vaccine;
  • Known immunodeficiency disorder;
  • Known HIV-infected mother;
  • Known thrombocytopenia or coagulation disorder;
  • Administration or planned administration of any immunoglobulin or blood product since birth;
  • Severe birth defect requiring ongoing medical care;
  • Chronic or progressive disease;
  • Seizure disorder;
  • History of severe illness;
  • Receipt of any 2 month vaccines through the Expanded Programme of Immunization (EPI) program;
  • Family plans on giving the infant Quinvaxem (DTP-Hib-HBV).

Additionally, enrolment will be deferred and infants asked to return to the health centre one week later for reassessment if they have at least one of the following deferral criteria:

  • Axillary temperature ≥37.5°C or ≤35.5°C;
  • Acute infection, especially bacterial;
  • Oral administration of corticoid therapy in past 14 days; or
  • Any of the following symptoms that interfere with normal activities: crying more than usual, sleeping more than usual, or loss of appetite.

Treatment and study plan

PCV Vaccine

Biological

PCV vaccination

Primary outcomes

  1. Carriage of Vaccine Type pneumococci

    Time frame: 12 months post vaccination, i.e. 24 months of age

    Evaluate the effect of a 0+1 PCV schedule administered at 12 months of age on Nasopharngeal Carrige (NP) carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls

  2. Carriage of Vaccine Type pneumococci

    Time frame: 12 months post last vaccination, i.e. 24 months of age

    Evaluate the effect of a 1+1 PCV schedule administered at 2 and 12 months of age on NP carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls.

Secondary outcomes

  1. Immunology sub-study

    Time frame: 12 months post vaccination, i.e. 24 months of age

    i) To evaluate the immune responses to a 0+1 PCV schedule at 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;

  2. Immunology sub-study

    Time frame: 12 months post last vaccination, i.e. 24 months of age

    ii) To evaluate the immune responses to a 1+1 PCV schedule at 2 and 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;

Sponsors and collaborators

Lead sponsor

Murdoch Childrens Research Institute

Other

Collaborators

  • Pasteur Institute, Ho Chi Minh City

Registry information

Official study title

Trial of Simplified Pneumococcal Vaccination in Vietnam II: The Herd Immunity Approach

Acronym: VPTII

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Apr 4, 2017
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.